| 489.1 3.21 (0.66%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 606.98 | 1-year : | 708.95 |
| Resists | First : | 519.67 | Second : | 606.98 |
| Pivot price | 484.3 |
|||
| Supports | First : | 475.46 | Second : | 448.14 |
| MAs | MA(5) : | 491.1  |
MA(20) : | 489.57 |
| MA(100) : | 462.9 |
MA(250) : | 465.78 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 74.4 |
D(3) : | 73.7 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 519.88 | Low : | 377.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VRTX ] has closed below upper band by 34.6%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 495.05 - 497.01 | 497.01 - 498.71 |
| Low: | 479.63 - 482.06 | 482.06 - 484.16 |
| Close: | 484.93 - 488.87 | 488.87 - 492.26 |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Thu, 10 Apr 2025
Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know - Nasdaq
Thu, 10 Apr 2025
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise - Yahoo Finance
Wed, 09 Apr 2025
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Tue, 08 Apr 2025
Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug” - Insider Monkey
Tue, 08 Apr 2025
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? - Yahoo Finance
Mon, 07 Apr 2025
Vertex to Announce First Quarter 2025 Financial Results on May 5th - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 257 (M) |
| Shares Float | 256 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 96.4 (%) |
| Shares Short | 5,750 (K) |
| Shares Short P.Month | 5,070 (K) |
| EPS | -2.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 63.86 |
| Profit Margin | -4.9 % |
| Operating Margin | 44.9 % |
| Return on Assets (ttm) | 12.6 % |
| Return on Equity (ttm) | -3.2 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 23.41 |
| Sales Per Share | 42.86 |
| EBITDA (p.s.) | 18.55 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | -493 (M) |
| Levered Free Cash Flow | 2,730 (M) |
| PE Ratio | -234.02 |
| PEG Ratio | 0 |
| Price to Book value | 7.65 |
| Price to Sales | 11.4 |
| Price to Cash Flow | -255.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|